Eric Lefkofsky Thinks Tempus Could Analyze a Cure for Cancer

Tempus wants to be the operating system for cancer treatment, and with forty percent of people in the United States receiving a diagnosis in their lifetime it could very much be needed. While the medical industry seems to be advancing their technology rapidly, this is not the case when it comes to how patient data is stored and processed. Eric Lefkofsky, co-founder of Tempus, knew he needed to change this when Liz, his wife, was given a breast cancer diagnosis. He watched as information was lost just between visits and treatments and wondered why information he thought should be in the records was not.

Not only does Lefkofsky want to fix the problems with data that was already collected but never properly processed, he wanted to introduce less mainstream data as part of regular patient care. Tempus wants to make a patient’s genetic and chemical makeup regularly included in their patient profile. This process would not only make finding the correct treatment for that patients more straightforward, but it would also make many diseases easier to prevent by showing red flags to doctors about things they are pre-disposed to chemically.

Tempus could potentially kickstart an infirmed medical industry by essentially e-enabling the whole process. Eric Lefkofsky is not a stranger to shaking up pre-existing industries, he also co-founded Lightbank. An hedge fund tech investment firm that focuses on disruptive technology startups that aren’t located in the traditional Silicon Valley. The company is located in Chicago and so are some of its investments.

Eric Lefkofsky has a passion for both cancer research and treatment and his current home and business headquarters of Chicago. While he graduated with a Juris Doctor from University of Michigan Law School, he is an adjunct professor at the University of Chicago. He serves on the Board of Trustees at the Steppenwolf Theatre of Chicago as Chairman. His charity, the Lefkofsky Foundation, focuses on initiatives that serve those in an around the Chicago area. He and his wife have joined the Giving Pledge and have promised to give at least half of their lietime wealth to altruistic causes.

To know more click: here.

Clay Siegall’s contributions to the Seattle Genetics company

If there is a company that boasts of its market value and fast development is the Seattle Genetics. The company’s value is currently attributed at $10 billion and with more than 900 enrolled employees. The company is also top ranking as the largest biotech in Washington.

Among the key factors to their success have been their heavy investment in research and marketing. It is one of the companies that has been undergoing vast developments and expansions that ensures an employment of more than 50 employees every year.

From the latest news from the directors of the company, they are currently in research to coming up with a drug to treat Hodgkin lymphoma. This is a cancer of the lymph systems that spread too fast to other body organs. They were captured claiming that if the ongoing expansive tests prove positive, its sales are expected to take off.

According to Clay Siegall, the co-founder and the current CEO of the company, Seattle Genetics is emerging to be a global, oncology and a multiproduct company. In line with this statement, he introduces a long list of the drugs that the company is dire to sell. He also points out on his plans to build the company not only to a great company but also to a larger company as so many biotech firms do.

It is true Siegalls ambitions are realistic more so when he talks of handling the complexities of the company to international marketing of its newer drugs. Under his leadership at Seattle, the company has made remarkable achievements and developments.

Back to his history, Dr. Clay Siegall is a man who has always led a successful life in all his previous engagements. Before he founded the Seattle Genetics, he was working with the Bristol Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. Before this, he had also worked with the National Institute of Health between 1988 and 1991.

His career was all shaped by his commitment to his education. He is a degree holder in zoology from the University of Maryland. After his degree course, he also proceeded to George Washington University where he received a PhD in Genetics.

In the current position, Clay Siegel serves as a Board of Directors at the Alder BioPharmaceuticals which is a private biotechnology company. More to this, he is also an author with more than 70 publications and 15 patents. Through the companies that he has made worked with, he has come to be recognized as a man who has always demonstrated his ability to dedicate his time and focus on his duties.